In patients with human epidermal growth factor receptor 2-positive breast cancer, increased GSDMB in tumor cells is associated with an increased incidence of metastasis, reduced survival, poor response to human epidermal growth factor receptor 2-targeted therapy, and poor prognosis. This evidence concerns the gene ERBB2 and breast carcinoma.